Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.
- The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.
- It is expected to increase patient access in the U.S. and has been published here on the CMS website.
- “The receipt of a product-specific J-code for iDose TR supports our market access initiatives to enable broad access and coverage for patients suffering from open-angle glaucoma or ocular hypertension,” said Thomas Burns, Glaukos chairman and chief executive officer.
- iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.